NCT03748966View on ClinicalTrials.gov

Calcitriol Monotherapy for X-Linked Hypophosphatemia

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

March 1, 2025

Study Completion Date

May 31, 2026

Conditions
X-linked HypophosphatemiaHypophosphatemic RicketsHypophosphatemic Rickets, X-Linked Dominant
Interventions
DRUG

Calcitriol

Adults and children (age 3-17) with X-linked hypophosphatemia will be treated with calcitriol therapy without phosphate supplementation. Doses of calcitriol will be escalated and optimized in the first three months of the study. Calcitriol is an oral medication taken once a day.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Massachusetts General Hospital

OTHER